Sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2, shows cytotoxic activity against poorly differentiated endometrial adenocarcinomas in vitro and in vivo.
Perrone E, Manara P, Lopez S, Bellone S, Bonazzoli E, Manzano A, Zammataro L, Bianchi A, Zeybek B, Buza N, Tymon-Rosario J, Altwerger G, Han C, Menderes G, Huang GS, Ratner E, Silasi DA, Azodi M, Hui P, Schwartz PE, Scambia G, Santin AD.
Perrone E, et al. Among authors: silasi da.
Mol Oncol. 2020 Mar;14(3):645-656. doi: 10.1002/1878-0261.12627. Epub 2020 Jan 14.
Mol Oncol. 2020.
PMID: 31891442
Free PMC article.